Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

Dissecting the functions of cancer-associated fibroblasts to therapeutically target head and neck cancer microenvironment

Abstract: Head and neck cancers (HNC) are a diverse group of aggressive malignancies with high morbidity and mortality, leading to almost half-million deaths annually worldwide. A better understanding of the molecular processes governing tumor formation and progression is crucial to improve current diagnostic and prognostic tools as well as to develop more personalized treatment strategies. Tumors are highly complex and heterogeneous structures in which growth and dissemination is not only governed by the cancer cells intrinsic mechanisms, but also by the surrounding tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) emerge as predominant TME components and key players in the generation of permissive conditions that ultimately impact in tumor progression and metastatic dissemination. Although CAFs were initially considered a consequence of tumor development, it is now well established that they actively contribute to numerous cancer hallmarks i.e., tumor cell growth, migration and invasion, cancer cell stemness, angiogenesis, metabolic reprograming, inflammation, and immune system modulation. In this scenario, therapeutic strategies targeting CAF functions could potentially have a major impact in cancer therapeutics, providing avenues for new treatment options or for improving efficacy in established approaches. This review is focused on thoroughly dissecting existing evidences supporting the contribution of CAFs in HNC biology with an emphasis on current knowledge of the key molecules and pathways involved in CAF-tumor crosstalk, and their potential as novel biomarkers and/or therapeutic targets to effectively interfere the tumor-stroma crosstalk for HNC patients benefit. involved in CAF-tumor crosstalk, and their potential as novel biomarkers and/or therapeutic targets to effec- tively interfere the tumor-stroma crosstalk for HNC patients benefit

 Autoría: Prieto-Fernández L., Montoro-Jiménez I., de Luxan-Delgado B., Otero-Rosales M., Rodrigo J.P., Calvo F., García-Pedrero J.M., Álvarez-Teijeiro S.,

 Fuente: Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie, 2023, 161, 114502

Editorial: Editions Scientifiques Elsevier

 Año de publicación: 2023

Nº de páginas: 16

Tipo de publicación: Artículo de Revista

 DOI: 10.1016/j.biopha.2023.114502

ISSN: 0753-3322,1950-6007

Url de la publicación: https://doi.org/10.1016/j.biopha.2023.114502

Autores/as

PRIETO-FERNÁNDEZ, LLARA

MONTORO-JIMÉNEZ, IRENE

BEATRIZ DE LUXAN-DELGADO

OTERO-ROSALES, MARÍA

RODRIGO, JUAN P.

GARCÍA-PEDRERO, JUANA M.

ÁLVAREZ-TEIJEIRO, SAÚL